[go: up one dir, main page]

MA27904A1 - Forme dosifiee orale de mesylate de saquinavir - Google Patents

Forme dosifiee orale de mesylate de saquinavir

Info

Publication number
MA27904A1
MA27904A1 MA28709A MA28709A MA27904A1 MA 27904 A1 MA27904 A1 MA 27904A1 MA 28709 A MA28709 A MA 28709A MA 28709 A MA28709 A MA 28709A MA 27904 A1 MA27904 A1 MA 27904A1
Authority
MA
Morocco
Prior art keywords
mesylate
saquinavir
saquinavir mesylate
disintegrant
solid
Prior art date
Application number
MA28709A
Other languages
English (en)
Inventor
Antonio A Albano
Martin Howard Infeld
Navnit-Hargovindas Shah
Lin Zhang
Wantanee Phuapradit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27904(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27904A1 publication Critical patent/MA27904A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une forme dosifiée pharmaceutique orale formant une unité solide de mésylate de saquinavir comprenant du mésylate de saquinavir microlysé, dans une quantité comprise entre 250 mg et 800 mg, calculée en tant que base libre, et un liant pharmaceutiquement acceptable, un désintégrant, un vecteur soluble dans l'eau. L'invention concerne une forme dosifiée formant une unité solide de mésylate de saquinavir comprenant entre 60 % et 80 % de mésylate de saquinavir microlysé, à base de sel de mésylate, de 4 à 8 % d'un liant soluble dans l'eau, un désintégrant et un vecteur, chaque pourcentage est calculé par rapport au poids de noyau.
MA28709A 2003-07-11 2006-01-06 Forme dosifiee orale de mesylate de saquinavir MA27904A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48660003P 2003-07-11 2003-07-11
US56820404P 2004-05-05 2004-05-05

Publications (1)

Publication Number Publication Date
MA27904A1 true MA27904A1 (fr) 2006-05-02

Family

ID=34068244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28709A MA27904A1 (fr) 2003-07-11 2006-01-06 Forme dosifiee orale de mesylate de saquinavir

Country Status (23)

Country Link
US (2) US20050009811A1 (fr)
EP (1) EP1646369B1 (fr)
JP (2) JP4608488B2 (fr)
KR (2) KR20070087194A (fr)
AU (1) AU2004255436B2 (fr)
BR (1) BRPI0412523A (fr)
CA (1) CA2531486C (fr)
CO (1) CO5640069A2 (fr)
CR (1) CR8172A (fr)
EA (1) EA015349B1 (fr)
EC (1) ECSP066274A (fr)
IL (1) IL172890A (fr)
MA (1) MA27904A1 (fr)
MX (1) MXPA06000363A (fr)
MY (1) MY140413A (fr)
NO (1) NO20060313L (fr)
NZ (1) NZ544585A (fr)
PA (1) PA8606001A1 (fr)
PE (1) PE20050247A1 (fr)
RS (1) RS20060009A (fr)
TN (1) TNSN06003A1 (fr)
TW (1) TWI356711B (fr)
WO (1) WO2005004836A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (fr) 1999-11-12 2011-04-26 Abbott Laboratories Inhibiteurs de cristallisation dans une dispersion solide
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2005004836A2 (fr) * 2003-07-11 2005-01-20 F.Hoffmann-La Roche Ag Forme dosifiee orale de mesylate de saquinavir
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP2168573A1 (fr) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations contentant d'ézétimibe
JP5818219B2 (ja) 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
MX2021004553A (es) * 2018-10-23 2021-07-16 Eastern Virginia Medical School Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DK1071402T3 (da) * 1998-04-09 2007-02-19 Hoffmann La Roche Fremgangsmåde til af partikler med (sub)mikronstörrelse ved oplösning i komprimeret gas og overfladeaktive stoffer
JP2002532406A (ja) * 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1247456A3 (fr) * 2001-02-28 2003-12-10 Pfizer Products Inc. Compositions pharmaceutiques savoureux pour les animaux domestiques
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
WO2005004836A2 (fr) * 2003-07-11 2005-01-20 F.Hoffmann-La Roche Ag Forme dosifiee orale de mesylate de saquinavir

Also Published As

Publication number Publication date
MXPA06000363A (es) 2006-03-28
KR20070087194A (ko) 2007-08-27
HK1089959A1 (en) 2006-12-15
CA2531486C (fr) 2012-10-02
EP1646369B1 (fr) 2019-04-10
IL172890A0 (en) 2006-06-11
PE20050247A1 (es) 2005-04-13
US20050009811A1 (en) 2005-01-13
CO5640069A2 (es) 2006-05-31
NZ544585A (en) 2008-04-30
CA2531486A1 (fr) 2005-01-20
AU2004255436A1 (en) 2005-01-20
CR8172A (es) 2006-10-04
TNSN06003A1 (en) 2007-10-03
AU2004255436B2 (en) 2006-11-30
KR20060056320A (ko) 2006-05-24
MY140413A (en) 2009-12-31
BRPI0412523A (pt) 2006-09-19
KR100767271B1 (ko) 2007-10-17
JP2010280707A (ja) 2010-12-16
JP4608488B2 (ja) 2011-01-12
ECSP066274A (es) 2006-10-25
TW200505504A (en) 2005-02-16
TWI356711B (en) 2012-01-21
EA200600156A1 (ru) 2006-08-25
US20090054481A1 (en) 2009-02-26
EA015349B1 (ru) 2011-06-30
IL172890A (en) 2013-11-28
NO20060313L (no) 2006-02-09
PA8606001A1 (es) 2005-03-03
WO2005004836A3 (fr) 2005-05-12
WO2005004836A2 (fr) 2005-01-20
EP1646369A2 (fr) 2006-04-19
RS20060009A (sr) 2008-06-05
JP2009501694A (ja) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
EP1659111A3 (fr) Derives de piperidine utiles comme des antagonistes de ccr5
MA26629A1 (fr) Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
MA24930A1 (fr) Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide
CA2371940A1 (fr) Amidon pregelatinise dans une formulation a liberation regulee
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
BG105173A (en) Novel salt form of pantoprazole
EE9800050A (et) Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine
EP1982713A3 (fr) Benzoxazoles substitués et analogues utilisés en tant qu'agents oestrogènes pour le traitement des maladies intestinales inflammatoires
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
TR200100812T2 (tr) Akut ağrı tedavisi için fentanil kompozisyon.
MA27123A1 (fr) Forme solide d'administration d'acide diphosphonique ou de sel de celui-ci, utilisant l'acide stearique comme lubrifiant, et procede pour la preparer
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
EP2179987A3 (fr) Traitement de la drépanocytose avec de dérivés héterocycliques carbaldehydes
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
MA27904A1 (fr) Forme dosifiee orale de mesylate de saquinavir
MA27498A1 (fr) Compositions pharmaceutiques de sertaconazole pour utilisation vaginale.
EP2452684A3 (fr) Micelles
MXPA04001933A (es) Composicion farmaceutica que comprende lumiracoxib.
CA2503211A1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
EP1637139A3 (fr) Nouvelle utilisation de composés inhibiteurs de la protéase du VIH